β-Blockers and Erectile Dysfunction in Heart Failure. Between Myth and Reality

Area of Science:

• Cardiology
• Urology
• Pharmacology

Background:

• Erectile dysfunction (ED) significantly impacts quality of life in heart failure (HF) patients.
• ED in HF is often underdiagnosed and untreated, despite its high prevalence.
• Shared risk factors, comorbidities, and physiological changes in HF contribute to ED.

Purpose of the Study:

• To review the association between ED and HF.
• To investigate the potential role of beta-blockers in causing or exacerbating ED in HF patients.
• To highlight the need for comprehensive ED management in HF.

Main Methods:

• Narrative review of existing scientific literature.
• Analysis of studies on ED in various settings, including arterial hypertension.
• Evaluation of methodological limitations in current research.

Main Results:

• The exact mechanisms linking ED and HF, particularly concerning beta-blockers, remain unclear.
• Existing studies on this topic often lack specific focus on HF patients.
• Beta-blockers are strongly recommended for HF management due to proven benefits in morbidity and mortality.

Conclusions:

• Beta-blockers should be continued at maximal tolerated doses for HF patients, irrespective of ED.
• Addressing ED in HF requires psychological support, risk factor modification, and careful medication selection.
• Specific treatments or devices may be considered for ED in select HF cases.